These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 14726221

  • 1. (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes.
    Takahata K, Shimazu S, Yoneda F.
    Pharmacol Res; 2004 Mar; 49(3):253-8. PubMed ID: 14726221
    [Abstract] [Full Text] [Related]

  • 2. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nicotine-induced release of noradrenaline from hypothalamic synaptosomes.
    Yoshida K, Kato Y, Imura H.
    Brain Res; 1980 Jan 27; 182(2):361-8. PubMed ID: 7357390
    [Abstract] [Full Text] [Related]

  • 10. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
    Azzaro AJ, King J, Kotzuk J, Schoepp DD, Frost J, Schochet S.
    J Neurochem; 1985 Sep 27; 45(3):949-56. PubMed ID: 3928811
    [Abstract] [Full Text] [Related]

  • 11. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J, Yu PH.
    Neuropharmacology; 1994 Jun 27; 33(6):763-8. PubMed ID: 7936114
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
    Finberg JP, Tenne M, Youdim MB.
    Br J Pharmacol; 1981 May 27; 73(1):65-74. PubMed ID: 6793119
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine.
    Fairbrother IS, Arbuthnott GW, Kelly JS, Butcher SP.
    J Neurochem; 1990 Jun 27; 54(6):1844-51. PubMed ID: 2338545
    [Abstract] [Full Text] [Related]

  • 18. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Mytilineou C, Cohen G.
    J Neurochem; 1985 Dec 27; 45(6):1951-3. PubMed ID: 3932598
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selegiline induces dopamine release through ATP-sensitive potassium channels in the rat caudate-putamen in vitro.
    Neusch C, Schnierle S, Moser A.
    Neurochem Int; 1997 Aug 27; 31(2):307-11. PubMed ID: 9220464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.